Skip to main content
Journal cover image

A phase 1 study investigating DX-2930 in healthy subjects.

Publication ,  Journal Article
Chyung, Y; Vince, B; Iarrobino, R; Sexton, D; Kenniston, J; Faucette, R; TenHoor, C; Stolz, LE; Stevens, C; Biedenkapp, J; Adelman, B
Published in: Ann Allergy Asthma Immunol
October 2014

BACKGROUND: DX-2930 is a human monoclonal antibody inhibitor of plasma kallikrein under investigation for long-term prophylaxis of hereditary angioedema. OBJECTIVE: To assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of DX-2930 in healthy subjects. METHODS: A single-center, double-blinded study was performed in 32 healthy subjects randomized 3:1 to receive a single subcutaneous administration of DX-2930 or placebo within 1 of 4 sequential, ascending dose cohorts (n = 8 each): 0.1, 0.3, 1.0, or 3.0 mg/kg. RESULTS: No dose-limiting toxicity was observed. Headache was the most commonly reported treatment emergent adverse event (AE), occurring at a rate of 25% in the DX-2930- and placebo-treated groups; none were severe and all resolved. There were no serious AEs, discontinuations owing to an AE, or deaths. Two subjects had a severe AE reported as related to treatment by the blinded investigator; the 2 AEs were asymptomatic creatinine phosphokinase elevations of 902 U/L in 1 subject receiving 0.1 mg/kg DX-2930 and 1,967 U/L in 1 subject receiving placebo. For the 0.1-, 0.3-, 1.0-, and 3.0-mg/kg dose groups, respectively, mean maximum plasma concentrations were 0.6, 1.4, 5.6, and 14.5 μg/mL and mean elimination half-lives were 20.6, 16.8, 17.6, and 21.2 days. Exploratory biomarker assays, involving ex vivo activation of the kallikrein pathway, showed dose- and time-dependent inhibition of plasma kallikrein, with evidence of sustained bioactivity consistent with the pharmacokinetics profile. CONCLUSION: A single administration of DX-2930 in healthy subjects up to doses of 3.0 mg/kg was well tolerated without dose-limiting toxicity. Pharmacokinetic and pharmacodynamic data provide evidence for a long-acting biological effect relevant to long-term prophylaxis for hereditary angioedema with C1-inhibitor deficiency. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01923207.

Duke Scholars

Published In

Ann Allergy Asthma Immunol

DOI

EISSN

1534-4436

Publication Date

October 2014

Volume

113

Issue

4

Start / End Page

460 / 6.e2

Location

United States

Related Subject Headings

  • Young Adult
  • Middle Aged
  • Male
  • Kallikreins
  • Humans
  • Healthy Volunteers
  • Female
  • Drug Administration Schedule
  • Double-Blind Method
  • Dose-Response Relationship, Drug
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Chyung, Y., Vince, B., Iarrobino, R., Sexton, D., Kenniston, J., Faucette, R., … Adelman, B. (2014). A phase 1 study investigating DX-2930 in healthy subjects. Ann Allergy Asthma Immunol, 113(4), 460-6.e2. https://doi.org/10.1016/j.anai.2014.05.028
Chyung, Yung, Bradley Vince, Ryan Iarrobino, Dan Sexton, Jon Kenniston, Ryan Faucette, Chris TenHoor, et al. “A phase 1 study investigating DX-2930 in healthy subjects.Ann Allergy Asthma Immunol 113, no. 4 (October 2014): 460-6.e2. https://doi.org/10.1016/j.anai.2014.05.028.
Chyung Y, Vince B, Iarrobino R, Sexton D, Kenniston J, Faucette R, et al. A phase 1 study investigating DX-2930 in healthy subjects. Ann Allergy Asthma Immunol. 2014 Oct;113(4):460-6.e2.
Chyung, Yung, et al. “A phase 1 study investigating DX-2930 in healthy subjects.Ann Allergy Asthma Immunol, vol. 113, no. 4, Oct. 2014, pp. 460-6.e2. Pubmed, doi:10.1016/j.anai.2014.05.028.
Chyung Y, Vince B, Iarrobino R, Sexton D, Kenniston J, Faucette R, TenHoor C, Stolz LE, Stevens C, Biedenkapp J, Adelman B. A phase 1 study investigating DX-2930 in healthy subjects. Ann Allergy Asthma Immunol. 2014 Oct;113(4):460–6.e2.
Journal cover image

Published In

Ann Allergy Asthma Immunol

DOI

EISSN

1534-4436

Publication Date

October 2014

Volume

113

Issue

4

Start / End Page

460 / 6.e2

Location

United States

Related Subject Headings

  • Young Adult
  • Middle Aged
  • Male
  • Kallikreins
  • Humans
  • Healthy Volunteers
  • Female
  • Drug Administration Schedule
  • Double-Blind Method
  • Dose-Response Relationship, Drug